Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | SELE | P16581 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 2/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.32 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397052 | 0.78 | ITGB1 (0.33) | ABCG2MEN1KMT2A | |
| SCHEMBL2816399 | 0.78 | AGTR1 (0.35) | AGTR1AGTR2ABCG2MEN1KMT2A | |
| SCHEMBL7795519 | 0.74 | ICAM1 (0.39) | KDM4CEP300CREBBPICAM1SELE | |
| SCHEMBL2818087 | 0.74 | NPC1 (0.40) | ABCG2DRD2DRD4DRD3MEN1 | |
| SCHEMBL11059345 | 0.70 | GBA1 (0.40) | — | |
| SCHEMBL4184332 | 0.70 | KDM4C (0.47) | KDM4CEP300CREBBPICAM1SELE | |
| SCHEMBL7004715 | 0.70 | ICAM1 (0.36) | KDM4CEP300CREBBPICAM1SELE | |
| SCHEMBL7795558 | 0.70 | ALDH1A1 (0.43) | KDM4CEP300CREBBPICAM1SELE | |
| SCHEMBL14650437 | 0.69 | KDM4C (0.39) | KDM4CEP300CREBBPICAM1SELE | |
| SCHEMBL17941564 | 0.69 | LMNA (0.42) | DRD2DRD4DRD3RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2246348-A1 | Coupling reactions useful in the preparation of (1h-tetrazol-5-yl)-biphenyl derivatives | Novartis AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-20100152458-A1 | COUPLING REACTIONS USEFUL IN THE PREPARATION OF (1H-TETRAZOL-5-YL) BIPHENYL DERIVATIVES | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| US-7700784-B2 | Coupling reactions useful in the preparation of (1h-tetrazol-5-yl) biphenyl derivatives | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-20070129413-A1 | Coupling reactions useful in the preparation of (1h-tetrazol-5-yl) biphenyl derivatives | NOVARTIS PHARMACEUTICALS CORPORATION | 2007-06-07 | — | — | US | disclosed |
| EP-1716140-A1 | COUPLING REACTIONS USEFUL IN THE PREPARATION OF (1H-TETRAZOL-5-YL)-BIPHENYL DERIVATIVES | Novartis AG (CH) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005075462-A1 | COUPLING REACTIONS USEFUL IN THE PREPARATION OF (1H-TETRAZOL-5-YL)-BIPHENYL DERIVATIVES | NOVARTIS AG (CH) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152458-A1 | COUPLING REACTIONS USEFUL IN THE PREPARATION OF (1H-TETRAZOL-5-YL) BIPHENYL DERIVATIVES | AGTR1, AGTR2, AGT | KDM4C 2575/4885EP300 2756/4885CREBBP 3331/4885 |
| US-20070129413-A1 | Coupling reactions useful in the preparation of (1h-tetrazol-5-yl) biphenyl derivatives | AGTR1, AGTR2, AGT | KDM4C 4188/4885EP300 4065/4885CREBBP 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.